The federal move on cannabis is not merely a policy shift. For land use, zoning, and real estate in New Jersey, it changes what property is worth and who will finance it. But it did not arrive the way most people expected, and that gap is where the opportunity lives.

Here is what actually happened. On April 23, 2026, Acting Attorney General Todd Blanche issued a final order, effective April 28, moving two narrow categories to Schedule III: marijuana in FDA-approved drug products, and marijuana subject to a state medical license. Everything else, including the adult-use market that dominates New Jersey’s industry, stays in Schedule I for now. A new expedited DEA hearing on rescheduling all cannabis begins June 29, 2026, and the April order is expected to draw legal challenges.

So we are on two tracks. Medical is through the door. Adult-use is standing at it. The track a parcel sits on determines what it is worth today versus what it could be worth by autumn.

The Land Use Impact

For years, federal prohibition cast a cloud over every cannabis land use application. Boards and neighbors pointed to federal illegality as grounds to oppose or delay. Rescheduling weakens that argument, decisively for medical and directionally for the rest, meaning fewer pretextual objections and stronger footing for site plans, variances, and conditional use approvals.

Municipal posture will follow the economics. Towns that adopted bans did so when the federal stance was hostile and the numbers looked ugly. As stabilized operators generate local revenue and reuse derelict buildings, expect a new wave of ordinance amendments, overlay districts, and redevelopment designations for uses that were once too politically risky.

Financing Doors Are Opening – on a Timeline

This is the game-changer, but it is sequenced, not instantaneous.

What opens now: For state-licensed medical operators, Section 280E is gone. That provision barred cannabis businesses from deducting ordinary expenses, taxing them on gross rather than net income. Congressional and industry analyses have estimated the resulting effective federal rate could reach as high as 70 to 80 percent. New Jersey operators already had state-level relief, since the state decoupled from 280E in 2023, so the federal change stacks on top of an existing benefit and makes the economics genuinely workable. Remove that federal burden and medical economics transform overnight – which is what conventional capital has waited for. Expect easier depository relationships, plausible acquisition and construction financing for medical-anchored real estate instead of all-cash and hard-money deals, and maturing net-lease and sale-leaseback structures.

What opens if the broad reclassification clears: The June 29 hearing is the gate to the larger thaw. If adult-use moves to Schedule III, the whole asset class re-rates, REITs and institutional capital gain a path in, cost of capital compresses, and conventional mortgage products come into reach. Whether agencies like the SBA follow suit will depend on updated policy guidance that has not yet been issued, but the predicate legal barrier falls away. One caveat for New Jersey’s many dual medical and adult-use dispensaries: it remains unsettled how 280E applies to a combined operation, and the IRS has issued no 2026 guidance. That ambiguity directly affects how to underwrite a tenant.

The land use effect is the same on both tracks: reasonably priced capital funds new construction, adaptive reuse of vacant industrial space and dead retail, and redevelopment-area development. Shelved projects get revisited. Sites that could not be capitalized for cannabis start to pencil out, medical first, then adult-use as the hearing resolves.

Why New Jersey Moves Fast

The CREAMM Act already gives the state a mature licensing and land use structure. The Cannabis Regulatory Commission has clear site suitability rules, and many municipalities have local cannabis zoning in place. Operators here do not need to build infrastructure from scratch; they can capitalize on expanded opportunity within an existing framework. Towns that opted in have a track record of approvals. Those that opted out face growing pressure to revisit positions that were never intended to be permanent.

Where the Friction Stays

Rescheduling is not legalization. Schedule III is still a controlled substance, the broad reclassification is unresolved pending June 29 and possible litigation, and interstate commerce remains closed. At the end of every analysis sits the gating item it has always been: local zoning discretion. A favorable federal posture does not entitle anyone to a variance. Treat anyone who characterizes this as a finished deal with caution.

The Bottom Line

If you own industrial, commercial, or mixed-use property in New Jersey, this moment should prompt a fresh look at highest and best use. Get site control before the re-rating, conduct your zoning due diligence early, separate medical-ready positions from adult-use-pending ones, and build your capital stack with June 29 on the calendar.

Rescheduling is the beginning of cannabis real estate becoming a conventional asset class. Those who move strategically now will capture outsized value. Those who wait for full legalization will find the opportunities already absorbed.

Murphy Schiller & Wilkes LLP (MSW) works with property owners, operators, and developers across New Jersey on land use approvals, zoning strategy, and cannabis real estate positioning. If you are evaluating a site and want to understand which track it sits on and what the next ninety days could mean, please contact us. Clients who move before June 29 will be the ones holding the right sites at the right basis when the rest of the market catches up.